Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intravenous ceftazidime with tobramycin vs oral ciprofloxacin Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of Pseudomonas aeruginosa from a… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Inhaled tobramycin (TNS) (28 days) vs TNS (56 days) Eradication of P aeruginosa from the respiratory tract: time to next isolation of P aeruginosa from BAL, sputum or oropharyngeal cultures · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory… Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Quality of life · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Adverse events · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD Time to next exacerbation · children aged 6 ‐ 18 with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD FEV1 · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Time to next exacerbation · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Participant satisfaction or preference · people with cystic fibrosis (age not given) Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Serum deposition (Cmax) · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD Adverse events · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Treatment time (minutes) · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Serum deposition Cmax · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Adverse events · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) FEV1 · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Time to next exacerbation · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Participant satisfaction or preference · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum deposition Cmax · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participant satisfaction or preference · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Treatment time · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Quality of life · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Serum deposition Cmax · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Adverse events · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD FEV1 · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Time to next exacerbation · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD Participant satisfaction or preference · children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Serum deposition Cmax · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering dornase alfa: conventional system vs VMT Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Treatment time · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serum deposition Cmax · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to next exacerbation · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Participant satisfaction or preference · adults and children with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Treatment time · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Quality of life · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Serum deposition Cmax · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |